ZURICH/LONDON, Oct 26 (Reuters) – Novartis raised its full-year core operating income guidance on Tuesday after strong third-quarter demand for its key cancer and multiple sclerosis drugs.
The Swiss drugmaker now expects core operating income to grow by a low single-digit percentage compared to the low single-digit decline previously expected. It maintained its forecast for low single-digit net sales growth.
(Reporting by Bhanvi Satija and Marleen Kaesebier, Editing by Friederike Heine)
Comments